PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF TANEZUMAB AS ADD-ON THERAPY TO OPIOID MEDICATION IN PATIENTS WITH PAIN DUE TO BONE METASTASES

Update Il y a 4 ans
Reference: EUCTR2008-005181-31

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective of this study is to evaluate the analgesic efficacy of single dose tanezumab 10 mg in combination with opioids (tanezumab 10 mg + opioids compared with opioids alone (placebo + opioids) in cancer patients with chronic pain due to bone metastases.


Inclusion criteria

  • PAIN DUE TO BONE METASTASES